Onyx Pharmaceuticals Reports Third Quarter 2009 Financial Results; Nexavar Global Net Sales Top $229 Million, 27% Increase Over Third Qu...(d to the Company's convertible senior...),Health

Date:11/3/2009

d to the Company's convertible senior notes were not included in diluted net income per share for the three and nine months ended September 30, 2009 because their effect would be anti-dilutive. ONYX PHARMACEUTICALS, INC. CALCULATION OF REVENUE FROM COLLABORATION AGREEMENT (In thousands, unaudited) Three Months Nine Months Ended September Ended September 30, 30, ---------------- ---------------- 2009 2008 2009 2008 ---- ---- ---- ---- Nexavar product revenue, net (as recorded by Bayer) $229,243 $180,887 $608,295 $501,303 ======== ======== ======== ======== Revenue subject to profit sharing (as recorded by Bayer) $199,774 $168,141 $548,093 $476,584 Combined cost of goods sold, distribution, selling, general and administrative expenses 76,309 79,362 222,531 222,200 ------ ------ ------- ------- Combined collaboration commercial profit $123,465 $88,779 $325,562 $254,384 ======== ======= ======== ======== Onyx's share of collaboration commercial profit $61,732 $44,390 $162,781 $127,192 Reimbursement of Onyx's shared marketing expenses 5,342 5,484 16,079 15,771 Royalty revenue 2,063 892 4,214 1,730 ----- --- ----- ----- Revenue from collaboration agreement $69,137 $50,766 $183,074 $144,693 =======
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related medicine news :

1. Cumberland Pharmaceuticals to Present at Lazard Healthcare Conference in New York on November 17, 2009
2. Vanda Pharmaceuticals Reports Third Quarter 2009 Results
3. Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
4. VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference
5. Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009
6. Amira Pharmaceuticals to Present at the BIO Investor Forum in San Francisco
7. Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation
8. DUSA Pharmaceuticals Named to Deloittes 2009 Technology Fast 500 List of Fastest Growing Companies in North America
9. Peregrine Pharmaceuticals Announces Implementation of 1:5 Reverse Stock Split to Take Effect October 19, 2009
10. Proteolix, Inc. to be Acquired By Onyx Pharmaceuticals
11. Amira Pharmaceuticals to Present at Montgomery Healthcare Conference